The European Investment Bank and the French pharmaceutical company Advicenne have signed a loan agreement of €20 million, supported by the European Fund for Strategic Investments, the heart of the Investment Plan for Europe, or Juncker Plan.

This agreement will allow Advicenne to strengthen its Research and Development activities and develop innovative medicines for patients suffering from rare diseases, especially children.